-
Mashup Score: 21
By Helen Cashman, Andrew J Wilson & 4 more. Our patient was a 36-year-old female who presented to hospital at 33 weeks pregnant with symptomatic COVID-19 infection.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 62How I treat newly diagnosed acute lymphoblastic leukemia | Published in Clinical Hematology International - 4 day(s) ago
By Giebel Sebastian. Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet-
«How I treat newly diagnosed acute lymphoblastic leukemia» - A comprehensive review published in Clin Hematol Int, the official academic peer reviewed open access journal of @TheIACH - No page charges or other hidden publication fees. https://t.co/hcnG97fScF
-
-
Mashup Score: 10
IACH News of the Week, curated by Dr Edwin Uriel Suárez , is a weekly summary of the latest advancements and discoveries in the field of hematology compiled in an easy-to-digest format. It highlights research breakthroughs, clinical trial results, interesting case studies, and important health advisories – all within the last week. This is a valuable tool for medical professionals with limited time to stay up-to-date on the ever-evolving world of hematology. Venetoclax plus decitabine as a bridge to
Source: iach.orgCategories: General Medicine News, Hem/OncsTweet-
RT @UsuarezMD: IACH News of the Week 6 | Oct | 2024 @TheIACH @Mohty_EBMT https://t.co/TP9RtsnHHH https://t.co/7qxzovYvrf
-
-
Mashup Score: 22
This IACH webinar will offer practical guidance for healthcare professionals on building and maintaining a positive online presence. Learn essential strategies for managing your virtual reputation, avoiding common pitfalls, and using social media to enhance patient trust and professional credibility in today’s digital world. Perfect for those looking to navigate social media effectively while upholding ethical medical standards. Speaker: Mohamad Mohty Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris. In addition to publishing more than 1000 peer-reviewed articles in stem cell transplantation, leukemia, and myeloma, Dr Mohty also s
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
Don’t miss this @TheIACH Webinar- Social media in medicine: a few tips on how to manage your virtual reputation https://t.co/0ukQtfNyHe
-
-
Mashup Score: 4
Abstract Objectives: To analyze the impact of prior therapies on outcomes with selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in 402 patients with relapsed/refractory multiple myeloma (RRMM) in the phase 3 BOSTON trial. Methods: Post hoc analysis of progression-free survival (PFS), overall survival (OS), and safety for lenalidomide-refractory, proteasome inhibitor (PI)-naïve, bortezomibnaïve, and one prior line of therapy (1LOT) patient subgroups. Results: At a median follow-up of over 28 months, clinically meaningful improvements in PFS were noted across all groups with SVd. The median SVd PFS was longer in all subgroups (lenalidomide-refractory: 10.2 vs. 7.1 months, PI-naïve: 29.5 vs. 9.7; bortezomib-naïve: 29.5 vs. 9.7; 1LOT: 21.0 vs. 10.7; p < .05). The lenalidomiderefractory subgroup had longer OS with SVd (26.7 vs. 18.6 months; HR 0.53; p = .015). In all subgroups, overall response and ≥very good partial response rates were higher with SVd
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: We are LIVE NOW! 🔽🔽🔽 https://t.co/7hAoKyfent Impact of prior treatment on selinexor,bortezomib, dexamethasone outcomes in pat…
-
-
Mashup Score: 24For Authors | Clinical Hematology International - 12 day(s) ago
Clinical Hematology International is an open-access journal supported by the International Academy for Clinical Hematology
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet-
Management of myeloma presenting as malignant spinal cord compression during pregnancy: a case report published in Clin Hematol Int, the peer-reviewed journal of @TheIACH (instructions to authors can be found at: https://t.co/bqEbenRUTN) https://t.co/SaMo2zlQq4
-
-
Mashup Score: 10
IACH News of the Week, curated by Dr Edwin Uriel Suárez , is a weekly summary of the latest advancements and discoveries in the field of hematology compiled in an easy-to-digest format. It highlights research breakthroughs, clinical trial results, interesting case studies, and important health advisories – all within the last week. This is a valuable tool for medical professionals with limited time to stay up-to-date on the ever-evolving world of hematology. Venetoclax plus decitabine as a bridge to
Source: iach.orgCategories: General Medicine News, Hem/OncsTweet-
RT @UsuarezMD: IACH News of the Week 6 | Oct | 2024 @TheIACH @Mohty_EBMT https://t.co/TP9RtsnHHH https://t.co/7qxzovYvrf
-
-
Mashup Score: 44Overview of approved CAR-T products and utility in clinical practice | Published in Clinical Hematology International - 21 day(s) ago
By Shakthi T Bhaskar, Bhagirathbhai Dholaria & 3 more. Since the first (CAR) T-cell product received FDA approval in 2017, studies have been completed that have led to approvals of CAR T-cells to treat a variety of malignancies.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet-
“Overview of approved CAR-T products and utility in clinical practice” published in Clin Hematol Int, the peer-reviewed journal of @TheIACH - A comprehensive analysis of the currently commercially available CAR T-cell products and their indications https://t.co/yUkXcdxeCs
-
-
Mashup Score: 44Overview of approved CAR-T products and utility in clinical practice | Published in Clinical Hematology International - 25 day(s) ago
By Shakthi T Bhaskar, Bhagirathbhai Dholaria & 3 more. Since the first (CAR) T-cell product received FDA approval in 2017, studies have been completed that have led to approvals of CAR T-cells to treat a variety of malignancies.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet-
“Overview of approved CAR-T products and utility in clinical practice” published in Clin Hematol Int, the peer-reviewed journal of @TheIACH - A comprehensive analysis of the currently commercially available CAR T-cell products and their indications https://t.co/yUkXcdxeCs
-
-
Mashup Score: 26Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease | Published in Clinical Hematology International - 26 day(s) ago
By Rahul Shah, Danielle Murphy & 13 more. We highlight the myriad impacts of cGVHD including and beyond the traditional organ systems captured by the National Institutes of Health Consensus Criteria, including iatrogenic complications of long-term immunosuppression.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet-
Multidisciplinary Management of Morbidities Associated with Chronic GVHD, Published in Clin Hematol Int, the peer-reviewed journal of @TheIACH : This review highlights the myriad impacts of cGVHD, including and beyond the traditional organ systems. https://t.co/Qwl0y9DgYS
-
“Untangling the clonal architecture in a case of AML with multiple cytogenetically unrelated clones” published in Clin Hematol Int, the academic peer-reviewed journal of @TheIACH -What a fascinating story deciphering the mystery of leukemia cells https://t.co/yDbTRo33sO